Login / Signup

ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets.

Glenn A MarshAlexander J McAuleyGough G AuSarah RiddellDaniel LaytonNagendrakumar B SinganallurRachel LaytonJean PaynePeter A DurrHannah BenderJennifer A BarrJohn BinghamVictoria BoydSheree BrownMatthew P BruceKathie BurkettTeresa EastwoodSarah EdwardsTamara GoughKim HalpinJenni HarperClare HolmesWilliam S J HormanPetrus Jansen van VurenSuzanne LowtherKate MaynardKristen D McAuleyMatthew J NeaveTimothy PooleChristina L RootesBrenton RoweElisha SoldaniVittoria StevensCameron R StewartWilly W SuenMary TachedjianShawn ToddLee TrinidadDuane WalterNaomi WatsonTrevor W DrewSarah C GilbertTeresa LambeSeshadri S Vasan
Published in: NPJ vaccines (2021)
Vaccines against SARS-CoV-2 are likely to be critical in the management of the ongoing pandemic. A number of candidates are in Phase III human clinical trials, including ChAdOx1 nCoV-19 (AZD1222), a replication-deficient chimpanzee adenovirus-vectored vaccine candidate. In preclinical trials, the efficacy of ChAdOx1 nCoV-19 against SARS-CoV-2 challenge was evaluated in a ferret model of infection. Groups of ferrets received either prime-only or prime-boost administration of ChAdOx1 nCoV-19 via the intramuscular or intranasal route. All ChAdOx1 nCoV-19 administration combinations resulted in significant reductions in viral loads in nasal-wash and oral swab samples. No vaccine-associated adverse events were observed associated with the ChAdOx1 nCoV-19 candidate, with the data from this study suggesting it could be an effective and safe vaccine against COVID-19. Our study also indicates the potential for intranasal administration as a way to further improve the efficacy of this leading vaccine candidate.
Keyphrases
  • sars cov
  • clinical trial
  • respiratory syndrome coronavirus
  • phase iii
  • coronavirus disease
  • stem cells
  • randomized controlled trial
  • risk assessment
  • cell therapy
  • induced pluripotent stem cells